

**Clinical Microbiology Market by Product (Instrument (Incubators), Analyzer (Microscope), Reagent, Kits, Media], Disease Area (Respiratory, Gastrointestinal, STD, UTI), End User (Hospitals, Diagnostic Center, Research Institutes) - Global Forecast to 2030**

Market Report | 2025-09-16 | 411 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The clinical microbiology market is projected to reach USD 7.34 billion by 2030, growing at a CAGR of 6.6% during the forecast period. The clinical microbiology market is witnessing strong growth, driven by advancements in diagnostic technologies such as rapid molecular testing and laboratory automation, which enable faster & accurate detection of infectious agents. In addition, the rising global burden of infectious diseases, fueled by population growth, urbanization, and increased international travel, further accelerates the demand for advanced microbiology testing solutions.

By product, the instruments segment accounted for the largest market share in 2024.

<https://www.marketsandmarkets.com/Images/microbiology-testing-market-Overview.webp>

The clinical microbiology market is segmented into instruments, reagents, and media & sera. The instruments segment accounted for the largest share of the market. This dominance is driven by several factors, including the widespread adoption of conventional laboratory instruments by researchers & academic institutions, alongside increasing industry-academia collaborations in genomic research. Additionally, molecular techniques and proteomics advancements, such as integrating microfluidics with PCR and applying nanotechnology to qPCR, are fuelling the growth.

By end user, the hospitals & diagnostic centers segment accounted for the largest share of the market in 2024.

The market is segmented by end user into hospitals & diagnostic centers, contract testing laboratories, and academic & research

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

institutes. In 2024, the hospitals & diagnostic laboratories segment accounted for the largest market share owing to the rising establishment of hospitals, the increasing outsourcing of R&D activities to diagnostic laboratories, the increasing burden of chronic diseases, and the ability of hospitals to invest in advanced healthcare infrastructure.

Asia Pacific is projected to grow at the highest CAGR during the forecast period.

The global clinical microbiology market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, contributing to increased healthcare spending across a broader population base. Additional growth drivers include the rising incidence and prevalence of infectious diseases, the modernization of healthcare infrastructure, and the growing adoption of advanced diagnostic technologies, particularly in rural areas. These factors are anticipated to create substantial growth opportunities for clinical microbiology companies in the Asia Pacific.

The break-up of the profile of primary participants in the clinical microbiology market:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in this market are bioMérieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Bruker Corporation (US), Hologic, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Siemens Healthineers AG (Germany), Shimadzu Corporation (Japan), and Neogen Corporation (US), among others.

Research Coverage:

This research report categorizes the clinical microbiology market by product (instruments, reagents, and media & sera), by disease area (respiratory diseases, bloodstream infections, gastrointestinal diseases, sexually transmitted diseases, urinary tract infections, periodontal diseases, and other diseases), by end user (hospitals & diagnostic centers, contract testing laboratories, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

Reasons To Buy This Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall clinical microbiology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

-□Analysis of key drivers (technological advancements in clinical diagnosis and novel molecular diagnostic-based instruments, rising incidence of infectious diseases and epidemics, increasing R&D programs and public-private investments), opportunities (improved healthcare infrastructure in emerging countries), restraints (limited reimbursement policies for clinical microbiology testing procedures), and challenges (operational barriers to diagnostic microbiology tests in emerging countries) influencing the growth of the clinical microbiology market.

-□Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the clinical microbiology market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the clinical microbiology market across varied regions.

-□Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical microbiology market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like bioMérieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the clinical microbiology market.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Table of Contents:

1	INTRODUCTION	35
1.1	STUDY OBJECTIVES	35
1.2	MARKET DEFINITION	35
1.3	MARKET SCOPE	36
1.3.1	MARKETS & REGIONS COVERED	36
1.3.2	INCLUSIONS & EXCLUSIONS	37
1.3.3	YEARS CONSIDERED	38
1.3.4	CURRENCY CONSIDERED	38
1.4	KEY STAKEHOLDERS	38
1.5	SUMMARY OF CHANGES	39
2	RESEARCH METHODOLOGY	40
2.1	RESEARCH DATA	40
2.2	RESEARCH APPROACH	40
2.2.1	SECONDARY DATA	41
2.2.1.1	Key secondary sources	41
2.2.1.2	Key data from secondary sources	42
2.2.2	PRIMARY DATA	43
2.2.2.1	Primary sources	43
2.2.2.2	Key data from primary sources	44
2.2.2.3	Key industry insights	45
2.2.2.4	Breakdown of primary interviews	45
2.3	MARKET SIZE ESTIMATION	46
2.3.1	BOTTOM-UP APPROACH	46
2.3.1.1	Approach 1: Company revenue estimation approach	47
2.3.1.2	Approach 2: Presentations of companies and primary interviews	47
2.3.1.3	Growth forecast	47
2.3.1.4	CAGR projections	48
2.3.2	TOP-DOWN APPROACH	48
2.4	MARKET BREAKDOWN & DATA TRIANGULATION	50
2.5	MARKET SHARE ASSESSMENT	51
2.6	RESEARCH ASSUMPTIONS	51
2.7	RESEARCH LIMITATIONS	51
2.8	RISK ASSESSMENT	52
3	EXECUTIVE SUMMARY	53
?		
4	PREMIUM INSIGHTS	57
4.1	CLINICAL MICROBIOLOGY MARKET OVERVIEW	57
4.2	CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)	58
4.3	CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2025 VS. 2030 (USD MILLION)	58
4.4	CLINICAL MICROBIOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)	59
4.5	CLINICAL MICROBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	59
5	MARKET OVERVIEW	60
5.1	INTRODUCTION	60
5.2	MARKET DYNAMICS	60
5.2.1	DRIVERS	61
5.2.1.1	Technological advancements and development of novel molecular diagnostic-based instruments	61

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.1.2 Rising incidence of infectious diseases and epidemics 62
- 5.2.1.3 Increasing focus on R&D programs and public-private investments 63
- 5.2.2 RESTRAINTS 64
  - 5.2.2.1 Limited reimbursement policies for clinical microbiology testing procedures 64
- 5.2.3 OPPORTUNITIES 64
  - 5.2.3.1 Improved healthcare infrastructure in emerging economies 64
- 5.2.4 CHALLENGES 65
  - 5.2.4.1 Operational barriers for diagnostic microbiology tests 65
- 5.3 PRICING ANALYSIS 65
  - 5.3.1 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY PRODUCTS 65
  - 5.3.2 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY TEST KITS, BY KEY PLAYER, 2023-2025 66
  - 5.3.3 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY PRODUCTS, BY REGION, 2023-2025 67
- 5.4 PATENT ANALYSIS 68
  - 5.4.1 LIST OF MAJOR PATENTS 69
- 5.5 VALUE CHAIN ANALYSIS 70
- 5.6 SUPPLY CHAIN ANALYSIS 71
- 5.7 TRADE ANALYSIS 72
  - 5.7.1 TRADE ANALYSIS FOR OPTICAL MICROSCOPES 72
  - 5.7.2 IMPORT DATA (HS CODE 9011) 73
  - 5.7.3 EXPORT DATA (HS CODE 9011) 73
- 5.8 ECOSYSTEM ANALYSIS 74
  - 5.8.1 CLINICAL MICROBIOLOGY MARKET: ROLE IN ECOSYSTEM 74
- 5.9 PORTER'S FIVE FORCES ANALYSIS 75
  - 5.9.1 THREAT OF NEW ENTRANTS 76
  - 5.9.2 THREAT OF SUBSTITUTES 76
  - 5.9.3 BARGAINING POWER OF BUYERS 76
  - 5.9.4 BARGAINING POWER OF SUPPLIERS 77
  - 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 77
- 5.10 REGULATORY LANDSCAPE 77
  - 5.10.1 REGULATORY FRAMEWORK 77
    - 5.10.1.1 North America 77
      - 5.10.1.1.1 US 77
      - 5.10.1.1.2 Canada 77
    - 5.10.1.2 Europe 78
      - 5.10.1.2.1 Germany 78
      - 5.10.1.2.2 UK 79
      - 5.10.1.2.3 France 79
      - 5.10.1.2.4 Italy 79
    - 5.10.1.3 Asia Pacific 80
      - 5.10.1.3.1 China 80
      - 5.10.1.3.2 Japan 80
      - 5.10.1.3.3 India 80
    - 5.10.1.4 Latin America 81
      - 5.10.1.4.1 Brazil 81
      - 5.10.1.4.2 Mexico 81
    - 5.10.1.5 Middle East 81

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.10.1.5.1	Africa	82
5.10.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	82
5.11	TECHNOLOGY ANALYSIS	84
5.11.1	KEY TECHNOLOGIES	84
5.11.1.1	MALDI-TOF mass spectrometry	84
5.11.2	COMPLEMENTARY TECHNOLOGIES	84
5.11.2.1	Optical immunosensors	85
5.11.2.2	Electrochemical immunosensors	85
5.11.3	ADJACENT TECHNOLOGIES	85
5.11.3.1	Automated multiplex PCR systems	85
5.12	KEY CONFERENCES & EVENTS, 2025-2026	85
5.13	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	87
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	88
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	88
5.14.2	BUYING CRITERIA	89
5.15	INVESTMENT & FUNDING SCENARIO	89
5.16	CASE STUDY ANALYSIS	90
5.16.1	CASE STUDY 1: IMPACT OF MALDI-TOF MS AND RAPID SUSCEPTIBILITY TESTING ON SEPSIS MANAGEMENT	90
5.16.2	CASE STUDY 2: IMPACT OF MULTIPLEX PCR PANELS IN MANAGING ACUTE GASTROENTERITIS IN ED	91
	?	
5.17	IMPACT OF AI/GENERATIVE AI IN CLINICAL MICROBIOLOGY MARKET	91
5.17.1	INTRODUCTION	91
5.17.2	MARKET POTENTIAL OF AI	92
5.17.3	AI-USE CASES	92
5.17.4	IMPLEMENTATION OF AI, BY KEY COMPANY & CASE	93
5.17.5	FUTURE OF AI IN CLINICAL MICROBIOLOGY MARKET	94
5.18	TRUMP TARIFF IMPACT ON CLINICAL MICROBIOLOGY MARKET	94
5.18.1	INTRODUCTION	94
5.18.2	KEY TARIFF RATES	95
5.18.3	PRICE IMPACT ANALYSIS	95
5.18.4	KEY IMPACT ON COUNTRY/REGION	96
5.18.4.1	North America	96
5.18.4.2	Europe	96
5.18.4.3	Asia Pacific	96
5.18.5	IMPACT ON END-USE INDUSTRIES	96
5.18.5.1	Hospitals & diagnostic centers	96
5.18.5.2	Contract testing laboratories	97
5.18.5.3	Academic & research institutes	97
6	CLINICAL MICROBIOLOGY MARKET, BY PRODUCT	98
6.1	INTRODUCTION	99
6.2	INSTRUMENTS	99
6.2.1	LABORATORY INSTRUMENTS	103
6.2.1.1	Incubators	106
6.2.1.1.1	Rising demand for cell culture applications to drive market	106
6.2.1.2	Gram stainers	109
6.2.1.2.1	Rapid, accurate screening of bacterial pathogens to fuel uptake	109

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.1.3 Bacterial colony counters 112
- 6.2.1.3.1 Increased focus on accurate bacterial quantification to drive market 112
- 6.2.1.4 Autoclave sterilizers 115
- 6.2.1.4.1 Increasing focus on infection control in healthcare facilities to support market growth 115
- 6.2.1.5 Microbial air samplers 118
- 6.2.1.5.1 Need for enhanced air quality monitoring in cleanrooms to accelerate segment growth 118
- 6.2.1.6 Anaerobic culture systems 121
- 6.2.1.6.1 Increased research on anaerobic microorganisms to boost segment growth 121
- 6.2.1.7 Petri dish fillers 124
- 6.2.1.7.1 Need for minimal bench space and effective control with graphical user interfaces to aid segment growth 124
- ?
- 6.2.1.8 Blood culture systems 127
- 6.2.1.8.1 Technological advancements in diagnostic testing to drive market 127
- 6.2.1.9 Microbial culture systems 130
- 6.2.1.9.1 Increase in biopharmaceutical research to augment segment growth 130
- 6.2.1.10 Other laboratory instruments 133
- 6.2.2 MICROBIOLOGY ANALYZERS 136
- 6.2.2.1 Molecular diagnostic instruments 140
- 6.2.2.1.1 Advancements in multiplexing techniques and high adoption of genomics-based analysis to aid market growth 140
- 6.2.2.2 Microscopes 143
- 6.2.2.2.1 Rising demand for high-resolution imaging to propel market 143
- 6.2.2.3 Mass spectrometers 146
- 6.2.2.3.1 Increased applications in proteomics & metabolomics to boost market 146
- 6.3 REAGENTS 148
- 6.3.1 PATHOGEN-SPECIFIC KITS 152
- 6.3.1.1 Increasing private-public initiatives for research to support market growth 152
- 6.3.2 GENERAL REAGENTS 154
- 6.3.2.1 Rising demand for diagnostic tests for pathogen detection to propel segment growth 154
- 6.4 MEDIA & SERA 157
- 6.4.1 RISING DEMAND FOR STANDARDIZED CULTURE MEDIA FOR MICROBIOLOGICAL TESTING TO PROPEL MARKET 157
- 7 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA 161
- 7.1 INTRODUCTION 162
- 7.2 RESPIRATORY DISEASES 162
- 7.2.1 EXPANSION OF RESPIRATORY DISEASE SURVEILLANCE PROGRAMS TO DRIVE MARKET 162
- 7.3 BLOODSTREAM INFECTIONS 166
- 7.3.1 GROWING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS TO DRIVE MARKET 166
- 7.4 GASTROINTESTINAL DISEASES 169
- 7.4.1 HIGH RISK OF FOOD- AND WATER-BORNE INFECTIONS TO AID MARKET 169
- 7.5 SEXUALLY TRANSMITTED DISEASES 172
- 7.5.1 INCREASING EMPHASIS ON EARLY & EFFECTIVE DISEASE DIAGNOSIS TO BOOST DEMAND 172
- 7.6 URINARY TRACT INFECTIONS 176
- 7.6.1 FOCUS ON PREVENTIVE CARE TO SUPPORT MARKET GROWTH 176
- 7.7 PERIODONTAL DISEASES 179
- 7.7.1 INCREASING R&D INITIATIVES TO STUDY MICROBE-INDUCED DISEASES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- TO FUEL MARKET 179
- 7.8 OTHER DISEASES 182
- 8 CLINICAL MICROBIOLOGY MARKET, BY END USER 186
  - 8.1 INTRODUCTION 187
  - 8.2 HOSPITALS & DIAGNOSTIC CENTERS 187
    - 8.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 187
  - 8.3 CONTRACT TESTING LABORATORIES 191
    - 8.3.1 LOW-COST OUTSOURCING OF TESTING ACTIVITIES TO LABORATORIES TO PROPEL MARKET 191
  - 8.4 ACADEMIC & RESEARCH INSTITUTES 194
    - 8.4.1 EXPANSION OF RESEARCH INITIATIVES AND FAVORABLE FUNDING INVESTMENTS TO BOOST MARKET 194
- 9 CLINICAL MICROBIOLOGY MARKET, BY REGION 197
  - 9.1 INTRODUCTION 198
  - 9.2 NORTH AMERICA 199
    - 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 204
      - 9.2.2 US 205
        - 9.2.2.1 Increasing prevalence of infectious diseases to drive market 205
      - 9.2.3 CANADA 209
        - 9.2.3.1 Supportive government initiatives and increased research funding to boost market 209
    - 9.3 EUROPE 213
      - 9.3.1 EUROPE: MACROECONOMIC OUTLOOK 217
        - 9.3.2 GERMANY 218
          - 9.3.2.1 Favorable government policies to propel market 218
        - 9.3.3 FRANCE 222
          - 9.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market 222
        - 9.3.4 UK 226
          - 9.3.4.1 Rising acceptance of genome-based diagnostic techniques to fuel market 226
      - 9.3.5 ITALY 230
        - 9.3.5.1 Improved healthcare services and better disease surveillance to support market growth 230
      - 9.3.6 SPAIN 234
        - 9.3.6.1 Growing focus on public healthcare initiatives to augment market growth 234
      - 9.3.7 REST OF EUROPE 238
    - 9.4 ASIA PACIFIC 242
      - 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 246
        - 9.4.2 CHINA 247
          - 9.4.2.1 Increasing government focus on disease prevention to drive market 247
        - ?
      - 9.4.3 JAPAN 251
        - 9.4.3.1 Technological advancements in diagnostic kits to fuel uptake 251
      - 9.4.4 INDIA 255
        - 9.4.4.1 High target patient population to boost demand 255
      - 9.4.5 SOUTH KOREA 259
        - 9.4.5.1 Favorable government initiatives for medical tourism to support market growth 259
    - 9.4.6 AUSTRALIA 263
      - 9.4.6.1 Favorable healthcare automation techniques to support market growth 263
    - 9.4.7 REST OF ASIA PACIFIC 267
  - 9.5 LATIN AMERICA 271
    - 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 275

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.5.2	BRAZIL	276
9.5.2.1	Universal healthcare access to drive market	276
9.5.3	MEXICO	279
9.5.3.1	Increasing prevalence of HIV to drive market	279
9.5.4	REST OF LATIN AMERICA	283
9.6	MIDDLE EAST & AFRICA	287
9.6.1	MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK	292
9.6.2	KINGDOM OF SAUDI ARABIA (KSA)	292
9.6.2.1	Increasing focus on healthcare automation to drive market	292
9.6.3	UNITED ARAB EMIRATES (UAE)	296
9.6.3.1	Improvements in healthcare infrastructure to support market growth	296
9.6.4	REST OF MIDDLE EAST & AFRICA	300
10	COMPETITIVE LANDSCAPE	304
10.1	INTRODUCTION	304
10.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	304
10.2.1	OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET	304
10.3	REVENUE SHARE ANALYSIS	307
10.4	MARKET SHARE ANALYSIS, 2024	308
10.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	310
10.5.1	STARS	310
10.5.2	EMERGING LEADERS	310
10.5.3	PERVASIVE PLAYERS	310
10.5.4	PARTICIPANTS	310
10.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	312
10.5.5.1	Company footprint	312
10.5.5.2	Region footprint	312
10.5.5.3	Product footprint	313
10.5.5.4	Instruments footprint	314
10.5.5.5	Disease area footprint	314
10.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	315
10.6.1	PROGRESSIVE COMPANIES	315
10.6.2	RESPONSIVE COMPANIES	315
10.6.3	DYNAMIC COMPANIES	315
10.6.4	STARTING BLOCKS	315
10.6.5	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	317
10.6.5.1	Detailed list of key startups/SMEs	317
10.6.5.2	Competitive benchmarking of startups/SMEs (1/2)	317
10.6.5.3	Competitive benchmarking of startups/SMEs (2/2)	318
10.7	COMPANY VALUATION & FINANCIAL METRICS	318
10.7.1	FINANCIAL METRICS	318
10.7.2	COMPANY VALUATION	319
10.8	BRAND/PRODUCT COMPARISON	319
10.8.1	BRAND/PRODUCT COMPARATIVE ANALYSIS	319
10.9	COMPETITIVE SCENARIO	320
10.9.1	PRODUCT/SERVICE LAUNCHES & APPROVALS	320
10.9.2	DEALS	321
10.9.3	EXPANSIONS	322

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11	COMPANY PROFILES	323
11.1	KEY PLAYERS	323
11.1.1	BIOMERIEUX	323
11.1.1.1	Business overview	323
11.1.1.2	Products/Services offered	325
11.1.1.3	Recent developments	327
11.1.1.3.1	Product/Service launches & approvals	327
11.1.1.3.2	Deals	328
11.1.1.4	MnM view	330
11.1.1.4.1	Key strengths	330
11.1.1.4.2	Strategic choices	330
11.1.1.4.3	Weaknesses & competitive threats	330
11.1.2	DANAHER CORPORATION	331
11.1.2.1	Business overview	331
11.1.2.2	Products/Services offered	333
11.1.2.3	Recent developments	334
11.1.2.3.1	Product/Service launches & approvals	334
11.1.2.3.2	Deals	335
11.1.2.3.3	Expansions	335
11.1.2.4	MnM view	336
11.1.2.4.1	Key strengths	336
11.1.2.4.2	Strategic choices	336
11.1.2.4.3	Weaknesses & competitive threats	336
11.1.3	BECTON, DICKINSON AND COMPANY (BD)	337
11.1.3.1	Business overview	337
11.1.3.2	Products/Services offered	338
11.1.3.3	Recent developments	340
11.1.3.3.1	Product/Service launches & approvals	340
11.1.3.3.2	Deals	341
11.1.3.3.3	Expansions	342
11.1.3.4	MnM view	342
11.1.3.4.1	Key strengths	342
11.1.3.4.2	Strategic choices	342
11.1.3.4.3	Weaknesses & competitive threats	342
11.1.4	THERMO FISHER SCIENTIFIC INC.	343
11.1.4.1	Business overview	343
11.1.4.2	Products/Services offered	344
11.1.4.3	Recent developments	347
11.1.4.3.1	Product/Service launches & approvals	347
11.1.4.3.2	Deals	348
11.1.4.4	MnM view	348
11.1.4.4.1	Key strengths	348
11.1.4.4.2	Strategic choices	348
11.1.4.4.3	Weaknesses & competitive threats	348
11.1.5	F. HOFFMANN-LA ROCHE LTD.	349
11.1.5.1	Business overview	349
11.1.5.2	Products/Services offered	350

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.5.3 Recent developments 351
  - 11.1.5.3.1 Product/Service launches & approvals 351
  - 11.1.5.3.2 Deals 352
  - 11.1.5.3.3 Expansions 352
- 11.1.5.4 MnM view 353
  - 11.1.5.4.1 Key strengths 353
  - 11.1.5.4.2 Strategic choices 353
  - 11.1.5.4.3 Weaknesses & competitive threats 353
- 11.1.6 ABBOTT LABORATORIES 354
  - 11.1.6.1 Business overview 354
  - 11.1.6.2 Products/Services offered 356
  - 11.1.6.3 Recent developments 361
    - 11.1.6.3.1 Deals 361
- 11.1.7 AGILENT TECHNOLOGIES, INC. 362
  - 11.1.7.1 Business overview 362
  - 11.1.7.2 Products/Services offered 363
  - 11.1.7.3 Recent developments 364
    - 11.1.7.3.1 Expansions 364
- 11.1.8 BRUKER CORPORATION 365
  - 11.1.8.1 Business overview 365
  - 11.1.8.2 Products/Services offered 366
  - 11.1.8.3 Recent developments 367
    - 11.1.8.3.1 Product/Service launches & approvals 367
    - 11.1.8.3.2 Deals 367
- 11.1.9 HOLOGIC, INC. 368
  - 11.1.9.1 Business overview 368
  - 11.1.9.2 Products/Services offered 369
  - 11.1.9.3 Recent developments 370
    - 11.1.9.3.1 Product/Service launches & approvals 370
    - 11.1.9.3.2 Deals 371
- 11.1.10 MERCK KGAA 372
  - 11.1.10.1 Business overview 372
  - 11.1.10.2 Products/Services offered 373
  - 11.1.10.3 Recent developments 374
    - 11.1.10.3.1 Deals 374
    - 11.1.10.3.2 Expansions 374
- 11.1.11 BIO-RAD LABORATORIES, INC. 376
  - 11.1.11.1 Business overview 376
  - 11.1.11.2 Products/Services offered 377
  - 11.1.11.3 Recent developments 379
    - 11.1.11.3.1 Deals 379
- 11.1.12 QIAGEN 380
  - 11.1.12.1 Business overview 380
  - 11.1.12.2 Products/Services offered 381
  - 11.1.12.3 Recent developments 382
    - 11.1.12.3.1 Product/Service launches 382
    - 11.1.12.3.2 Deals 383

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.12.3.3	Expansions	383
11.1.13	SIEMENS HEALTHINEERS AG	384
11.1.13.1	Business overview	384
11.1.13.2	Products/Services offered	385
11.1.13.3	Recent developments	386
11.1.13.3.1	Product/Service launches	386
11.1.13.3.2	Deals	386
11.1.13.3.3	Expansions	387
?		
11.2	OTHER PLAYERS	388
11.2.1	SHIMADZU CORPORATION	388
11.2.2	NEOGEN CORPORATION	389
11.2.3	SEEGENE INC.	390
11.2.4	RAPID MICRO BIOSYSTEMS, INC.	391
11.2.5	HARDY DIAGNOSTICS	392
11.2.6	EMSL ANALYTICAL, INC.	395
11.2.7	LIOFILCHEM S.R.L.	396
11.2.8	TCS BIOSCIENCES LTD.	397
11.2.9	MEMMERT GMBH + CO.KG	398
11.2.10	VACUTEST KIMA S.R.L.	399
11.2.11	CREATIVE DIAGNOSTICS	400
11.2.12	DCN DX	401
12	APPENDIX	402
12.1	DISCUSSION GUIDE	402
12.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	407
12.3	CUSTOMIZATION OPTIONS	409
12.4	RELATED REPORTS	409
12.5	AUTHOR DETAILS	410

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Clinical Microbiology Market by Product (Instrument (Incubators), Analyzer (Microscope), Reagent, Kits, Media], Disease Area (Respiratory, Gastrointestinal, STD, UTI), End User (Hospitals, Diagnostic Center, Research Institutes) - Global Forecast to 2030**

Market Report | 2025-09-16 | 411 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code\*

Country\*

Date

2026-03-16

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com